TScan is a clinical-stage biopharmaceutical company dedicated to creating life-changing T cell therapies for patients by unleashing the untapped potential of the human immune system. Interested in joining our team? Explore Careers.

To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in …

TScan is a clinical-stage biopharmaceutical company dedicated to changing lives by discovering new cancer targets and developing safe and effective T cell receptor (TCR)-engineered therapies (TCR-T) for the treatment of patients with cancer.

Find the TScan Therapeutics style guide with brand assets such as logos, colors, fonts, and more.

TScan is leveraging our proprietary platform technologies to develop a robust pipeline of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer.

在2019年就用Python写过指纹识别工具—— TideFinger ，并实现了一个免费在线的指纹检测平台——潮汐指纹 finger.tidesec.com ， 目前已积累用户3万余人，每日指纹识别约2000余次，2023年初又基于Go语言开发了Go版的 TideFinger_Go ，在web指纹和服务指纹的识别方面积累了一些经验。 后来我们团队内部大佬基于Fscan开发了一个Tscan，主要是用于内部的POC收集整理并形成自动化武器库，可基于指纹识别结果对poc进行精准检测。 无影 (TscanPlus)就是以指纹 …

TScan Therapeutics is a fully integrated, next-generation TCR-T cell therapy company. Founded in 2018, TScan’s platform was developed by Stephen Elledge, Ph.D., and Tomasz Kula, Ph.D., at...

TScan Therapeutics logo en format d'icone. Format PNG Format SVG. TScan Therapeutics logo grand pour les fonds sombres. Format PNG Format SVG. À propos de TScan Therapeutics. Dernière mise à jour le: 06/07/2024. Signaler le logo comme obsolète. Categories: 🇺🇸 États-Unis 💊 Pharmaceutiques 🧬 Biotechnologie.

2024年11月20日 · •The ALLOHA Study (TSCAN-001, NCT05473910) is a Phase 1, multi-center, biologically controlled study evaluating TSC-100 in HA-1 and TSC-101 in HA-2 positive adult patients with AML, ALL, or MDS undergoing RIC-HCT

2021年7月12日 · TScan Therapeutics was founded in 2018 and booked $3 million in collaboration and license revenue for the 12 months ended March 31, 2021. It plans to list on the Nasdaq under the symbol TCRX.